Synthesis and application of photochemical integrated adipocyte exosome bionic prodrug nanoparticles

By synthesizing oxidative-lipase-sensitive docetaxel derivatives and protoporphyrin derivatives, the preparation of actinic adipocyte exosome bionic prodrug nanoparticles, solving chemotherapeutic drugs and photosensitizers in the treatment of hepatocellular carcinoma The problem of low targeting and large side effects has achieved specific release of tumor sites and efficient anti-tumor effects.

CN118903046APending Publication Date: 2024-11-08SHENYANG PHARMA UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410920878.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-10
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing chemotherapeutic drugs such as docetaxel and photosensitizer protoporphyrin have problems such as low targeting, large side effects and poor organ selectivity in the treatment of hepatocellular carcinoma, making it difficult to achieve space-time release of tumor sites, and photodynamic-chemotherapy Combination therapy requires the design of appropriate drug delivery systems to overcome these limitations.

Method used

Design and synthesize docetaxel derivatives with oxidative-lipase bisensitivity and protoporphyrin derivatives with good fat-soluble properties to prepare actinic adipocyte exosomes bionic prodrug nanoparticles, and use adipocyte exosomes. The camouflage and monosulfide bond structure achieve tumor-specific release in a high oxidative environment.

Benefits of technology

Improve the targeting of docetaxel and the fat solubility of photosensitizers, achieve specific release in tumor sites, reduce system toxicity, enhance anti-tumor effects, and pass the camouflage and high oxidation of fat cell exosomes Environmental response improves the targeting and release efficiency of drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903046A_ABST
    Figure CN118903046A_ABST
Patent Text Reader

Abstract

The invention discloses synthesis and application of photochemical integrated adipocyte exosome bionic prodrug nanoparticles, and belongs to the technical field of medicines.The nanoparticles are provided with bionic shells of adipocyte exosomes, so that the nanoparticles can stably exist in a normal physiological environment, reach tumor sites in a targeted mode after intravenous injection, and can be used for treating tumor tumors. The specific release of the parent drug in the tumor cells is realized in an abnormally high oxidation environment in the tumor cells; the prodrug is composed of a protoporphyrin derivative and a docetaxel derivative. A new strategy and more choices are provided for improving the defects of docetaxel in clinical application and developing a tumor microenvironment intelligent response type drug delivery system, and the application prospect is large.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and relates to the synthesis of photochemically integrated adipocyte exosome bionic prodrug nanoparticles and their application in drug delivery. Background Art

[0002] The high incidence and mortality of hepatocellular carcinoma (HCC) pose a major threat to human health. Combining chemotherapy drugs with photodynamic therapy has the advantages of less trauma, good applicability and repeatable treatment, and has become an emerging strategy in the field of cancer treatment. However, traditional chemotherapy drugs currently have disadvantages such as inability to effectively avoid phagocytosis by the reticulum macrophage system and low targeting. The biomimetic exosome membrane coating technology can not only improve the biocompatibility and prolong the blood circulation time by coating nanoparticles with exosome membranes, but also play a natural targeting role in the body and is widely used in clinical research.

[0003] Docetaxel (Docetaxel, DTX) is a commonly used anti-tumor chemotherapy drug in clinical practice. It achieves therapeutic effects by inhibiting the division and growth of tumor cells. It shows certain efficacy in patients with liver cancer, especially in patients with advanced liver cancer. However, due to its organ non-selectivity, docetaxel has the following side effects including fatigue, nausea, hair loss, hepatotoxicity and renal toxicity, and vomiting. Docetaxel also has relatively special side effects, namely water and sodium retention and allergy. Therefore, improving the targeting of docetaxel is of great significance for its clinical use. Protoporphyrin (Protoporphyrin IX, PpIX) is an endogenous photosensitizer with good safety and significant efficacy, but due to its poor organ selectivity and low lipid solubility, it has many limitations in clinical treatment. It is worth noting that the combination of photodynamic therapy and chemotherapy has become a particularly new anti-cancer strategy. This multimodal therapy can overcome the limitations of single chemotherapy mode treatment to achieve a synergistic effect on tumors, surpassing the addition of a single therapy, and has a synergistic effect. However, since photosensitizers and chemotherapeutic drugs usually have disadvantages such as poor solubility, rapid elimination from the body, and non-specific distribution, and their in vivo behaviors are also significantly different, it is difficult to achieve spatiotemporal consistency at the tumor site after administration. Therefore, photodynamic-chemotherapy combination therapy also requires the design of a suitable drug delivery system to achieve targeting of tumor cells in the systemic circulation and rapid and specific release at the tumor site.

[0004] The reactive oxygen species (ROS) in a large number of primary tumors and tumor cell lines are higher than those in normal cells, resulting in a highly oxidative microenvironment in the tumor. Therefore, drugs can be derivatized based on the highly oxidative environment of the tumor to make them oxidatively sensitive. ROS-responsive groups generally contain three elements: sulfur, boron, and thiol. Common ROS-responsive groups include monosulfide bonds, thiols, etc., among which monosulfide bonds have better ROS responsiveness. In addition, the communication between cancer cells and obesity-related adipocyte exosomes in patients with liver cancer is significantly enhanced, and the adipocyte exosomes of obese patients have the potential for targeted treatment of liver cancer cells.

[0005] In summary, improving the adverse effects of adipocyte exosome-inspired bionic prodrug nanoparticles through structural modification design and synthesis has far-reaching significance for targeted delivery and combined chemotherapy and photodynamic therapy of liver cancer. Summary of the invention

[0006] The technical problem solved by the present invention is to design and synthesize a photochemically integrated adipocyte exosome bionic prodrug nanoparticle, which has a bionic shell of adipocyte exosomes, so that it can stably exist under normal physiological conditions, can be targeted to the tumor site after intravenous injection, and can achieve specific release of the parent drug in tumor cells under the abnormally high oxidation environment in tumor cells, and has excellent clinical transformation prospects.

[0007] In order to achieve the above-mentioned object, the present invention provides an oxidative-lipase dual-sensitive docetaxel derivative (DSTG) as shown in structure (I) and a protoporphyrin derivative (PPLA) with good lipid solubility as shown in structure (II): and photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles are prepared, and the flow chart is as follows: Figure 7 As shown:

[0008]

[0009] The DSTG synthesis method provided by the present invention comprises the following steps:

[0010]

[0011] 1,3-Dihydroxyacetone and linoleic acid were dissolved in anhydrous dichloromethane, and catalysts 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) and 4-dimethylaminopyridine (DMAP) were added, and the mixture was stirred at 0°C for 2 hours for esterification to obtain an intermediate product. The intermediate product was dissolved in a tetrahydrofuran-benzene (5:1) mixed solvent, and ultrapure water with a total volume of 1 / 10 was added, and the mixture was stirred at 0°C for 30 minutes, and then sodium borohydride solid powder was added, and the mixture was stirred at room temperature for 30 minutes to obtain compound 1.

[0012]

[0013] Acetic anhydride was added to monothiodipropionic acid in a circular dropwise manner and stirred at 25°C for 2 hours. After the reaction was completed, the reaction solution was subjected to rotary evaporation to remove the acetic anhydride. Anhydrous dichloromethane was added to re-dissolve, and compound 1 and catalyst DMAP were added to heat the mixture to 25°C and reacted under nitrogen protection for 12 hours. After the reaction was completed, the reaction solution was dried by rotary evaporation and purified by silica gel chromatography to obtain compound 2.

[0014]

[0015] Compound 2 was weighed, and catalyst DMAP and EDCI were added, and the mixture was stirred at 0°C for 2 hours. After the reaction, docetaxel was added to the reaction solution, and the mixture was stirred at room temperature for 24 hours. After the reaction, the final product, compound 3, was purified by silica gel chromatography to obtain the final product.

[0016] The PPLA synthesis method provided by the present invention comprises the following steps:

[0017]

[0018] Dissolve linoleic acid in anhydrous dichloromethane, add catalyst EDCI and DMAP, and stir at 0°C for 2h. After the reaction is completed, ethylene glycol is added dropwise to the above reaction solution, and the temperature is raised to 25°C and stirred for 12h. The impurities in the crude product are separated by continuously adding mobile phases of different proportions (petroleum ether and ethyl acetate = 30:1-1:1, v / v). The mobile phase starts with a volume ratio of petroleum ether and ethyl acetate of 30:1, and the product separation is detected by thin layer chromatography. When the mobile phase ratio is 2:1, the mobile phase flowing out of the silica gel column is collected and spin-dried to compound 1.

[0019]

[0020] PpIX was dissolved in anhydrous dichloromethane, and catalysts EDCI and DMAP were added to react at 0°C for 2h. After the reaction, compound 1 was dissolved in anhydrous dichloromethane and added to the above reaction solution, and the temperature was raised to 25°C and stirred for 12h. After the reaction, the impurities in the crude product were separated by continuously adding mobile phases in different ratios (petroleum ether and ethyl acetate = 20:1-1:1, v / v). The mobile phase was petroleum ether and ethyl acetate in a volume ratio of 20:1. Thin layer chromatography was used to detect the separation of the products. When the mobile phase ratio was 1.5:1, the mobile phase flowing out of the silica gel column was collected and dried to obtain the final product PPLA.

[0021] The method for preparing the photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles provided by the present invention comprises the following steps:

[0022] In order to obtain functional adipocyte-derived exosomes, the "cocktail" differentiation method of palmitic acid-simulated obesity conditions was used to induce 3T3-L1 mouse preadipocytes into mature adipocytes. After induction, the old culture medium was gently aspirated, and the supernatant was aspirated with a pipette after treatment with or without high-fat conditions and transferred to an ultrafiltration tube. The precipitate obtained by ultraspeed gradient centrifugation was high-fat adipocyte exosomes (hereinafter referred to as HEM) and non-high-fat treated adipocyte exosomes (hereinafter referred to as NEM). The docetaxel derivative prodrug and the protoporphyrin derivative prodrug were prepared with HEM or NEM by co-extrusion to obtain photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles (HEMPs and NEMPs). The protoporphyrin derivative prodrug and the docetaxel derivative prodrug were mixed at a mass ratio of 10:1 to 1:10.

[0023] Application of the photochemically integrated adipocyte exosome bionic prodrug nanoparticles of the present invention in the preparation of a drug delivery system.

[0024] The photochemically integrated adipocyte exosome bionic prodrug nanoparticles of the present invention are used in the preparation of cancer targeted therapeutic drugs.

[0025] The photochemically integrated adipocyte exosome bionic prodrug nanoparticles of the present invention are used in the preparation of injection, oral or local drug delivery systems.

[0026] The advantages of the present invention are: ① docetaxel is prepared into an oxidation-sensitive prodrug, which reduces the systemic toxicity of docetaxel and can achieve the specific release of the parent drug at the tumor site, achieving the effect of increasing efficacy and reducing toxicity; ② the photosensitizer protoporphyrin is modified with unsaturated fatty acid chains to improve its poor lipid solubility; ③ the targeting of the prodrug is increased through the camouflage of fat cell exosomes, and intelligent drug release at the tumor site can be achieved; ④ the single sulfide bond structure and triglyceride structure of the core lipid droplet nanoparticles of the bionic exosome can be oxidatively broken in the high oxidation and high lipase environment of the tumor site, and the drug release efficiency is greatly increased after external laser irradiation activation, so that the docetaxel parent drug is released only after the drug reaches the tumor site, and reactive oxygen and lipid peroxidation effects are generated to kill tumor cells, achieving anti-tumor effects. It provides new strategies and more options for improving the shortcomings of docetaxel in clinical applications and developing intelligent responsive drug delivery systems for tumor microenvironment, and has great application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1-2 The docetaxel derivative of Example 1 of the present invention 1 HNMR spectra and mass spectra.

[0028] Figure 3-4 The protoporphyrin derivative of Example 2 of the present invention 1HNMR spectra and mass spectra.

[0029] Figure 5-6 This is a graph showing the in vitro release experiment of the docetaxel-protoporphyrin derivative of Example 3 of the present invention.

[0030] Figure 7 This is a flow chart for preparing the photochemically integrated adipocyte exosome bionic prodrug nanoparticles of Example 4 of the present invention.

[0031] Figure 8 The BCA standard curve is shown in Figure 2. The horizontal axis represents the OD value, and the vertical axis represents the concentration (μg / μL).

[0032] Figure 9-10 This is a pharmacodynamics experiment diagram of the photochemically integrated adipocyte exosome bionic prodrug nanoparticles of Example 6 of the present invention. Fig. 9 (A) Molar concentration-time curves of HEMPs, NEMPs, NPs and Sol; (BC) AUC and T 1 / 2 Parameters; (A represents HEMPs, B represents NEMPs, C represents NPs, and D represents Sol). Fig.10 (A) Schematic diagram of drug administration; (B) Tumor volume curve; (C) Tumor bearing rate.

[0033] Fig.11 These are images of tumors after treatment; 1: Saline, 2: Sol, 3: Sol(+), 4: NPs, 5: NP(+), 6: NEMPs, 7: NEMPs(+), 8: HEMPs, 9: HEMPs(+).

[0034] Fig.12 Fluorescence images of normal tissues and tumors at 4, 8, 12, and 24 h after intravenous injection of Sol, NPs, NEMPs, and HEMPs. DETAILED DESCRIPTION

[0035] The present invention is further described below by way of examples, but the invention is not limited to the scope of the examples.

[0036] Example 1: Synthesis of docetaxel derivatives

[0037] Linoleic acid (3.8 g, 2.5 mol) was added to a 250 mL eggplant-shaped bottle and dissolved in 40 mL of anhydrous dichloromethane. At 0 ° C, EDCI (4.2 g, 4 mol) and DMAP (1.35 g, 2 mol) were slowly added to the above reaction system and activated for 2 h under nitrogen protection. After activation, 1,3-dihydroxyacetone (0.5 g, 1 mol) was dissolved in anhydrous dichloromethane and slowly added to the above solution. After the addition was completed, the temperature was raised to 25 ° C and reacted for 12 h under nitrogen protection. After the reaction was completed, the reaction solution was extracted with a saturated sodium chloride-20% citric acid solution. After the extraction was completed, the reaction solution was spin-dried and purified by silica gel chromatography to obtain intermediate 1.

[0038] Add intermediate 1 (2g, 1mol) to a 250mL eggplant-shaped bottle and add 36mL of tetrahydrofuran-benzene (5:1, v / v) mixed solvent to dissolve. At 0°C, slowly add 3.6mL of ultrapure water to the reaction solution and activate it for 30min under nitrogen protection. After activation, weigh 500mg of sodium borohydride solid powder and slowly add it to the above reaction solution. After the addition is complete, heat the temperature to 25°C and react for 30min under nitrogen protection. After the reaction is completed, add 1mL of glacial acetic acid, extract the reaction solution three times with saturated sodium chloride-5% sodium bicarbonate solution, add anhydrous sodium sulfate to the extract, let it stand for 30min, then filter it with suction, rotary evaporate the above reaction solution, and weigh to obtain compound 1 (2g).

[0039] Add monothiodipropionic acid (1g, 1.5mol) to a 100mL eggplant-shaped bottle, add 8mL of acetic anhydride in a circular drop, heat to 25°C, and react for 2h under nitrogen protection. After the reaction is completed, remove acetic anhydride from the reaction solution by rotary evaporation. Add 30mL of anhydrous dichloromethane to dissolve, add compound 1 (2g, 1mol) and DMAP (40mg, 0.1mol), heat to 25°C, and react for 12h under nitrogen protection. After the reaction is completed, the reaction solution is dried and purified by silica gel chromatography to obtain compound 2 (894mg).

[0040] Weigh compound 2 (461 mg, 1.2 mol), add it to a 100 mL eggplant-shaped bottle, dissolve it with 20 mL of anhydrous dichloromethane, add DMAP (6 mg, 0.1 mol) and EDCI (94 mg, 1 mol) to the above reaction solution at 0 ° C, and activate it under nitrogen protection for 2 hours. After the reaction is completed, docetaxel (400 mg, 1 mol) is dissolved in 3 mL of anhydrous dichloromethane and added dropwise to the above reaction solution. After the addition is completed, the temperature is raised to 25 ° C and reacted under nitrogen protection for 24 hours. After the reaction is completed, the final product, compound 3 (300 mg), is purified by silica gel chromatography.

[0041] Mass spectrometry and nuclear magnetic resonance spectroscopy were used to determine the structure of the prodrug in Example 1. The results are as follows: Figure 1 and Figure 2 The results of NMR spectrum analysis are as follows: DSTG (C 88 H 127 NO 21 SNa)

[0042] Figure 1 : 1 H NMR spectrum of DSTG. 1 H NMR (600MHz, Chloroform-d) δ8.13 (d, J = 7.6Hz, 2H; 2-methylene protons),7.63(t,J=7.5Hz,1H;1-CH),7.53(t,J=7.7Hz,2H;2-CH),7.36(dd,J=53.2,7.8Hz,5H;5-CH),6.25(s,1H;1-CH),5.7 1(d,J=7.1Hz,1H;1-NH),5.47(s,1H;1-CH),5.43–5.36(m,5H;5-CH),5.35–5.28(m,10H;5-CH2),5.24-5.17(s,2H;2-CH),4.99( d,J=8.9Hz,1H;1-CH),2.86–2.70(m,8H;4-CH2),2.64-2.45(s,10H;5-CH2),2.37–2.31(m,2H;1-CH2),2.23(d,J=7.8Hz,1H;1- CH), 2.07–1.97 (m, 8H; 4-CH2), 1.65 (td, J = 16.3, 14.2, 9.5Hz, 14H; 7-CH2), 1.25-1.14 (s, 6H; 2-CH3), 0.92–0.89 (m, 6H; 2-CH3).

[0043] Figure 2 :Mass spectrometry results: ESI-MS (m / z): [M+Na] + =1588.85198.

[0044] Example 2: Synthesis of protoporphyrin derivatives

[0045] Linoleic acid (2.1g, 2mol) was added to a 100mL eggplant-shaped bottle and dissolved with 30mL of anhydrous dichloromethane. At 0°C, EDCI (0.5g, 0.95mol) and DMAP (0.08g, 0.2mol) were slowly added dropwise to the above reaction system and activated for 2h under nitrogen protection. After activation, ethylene glycol (2mL, 2mol) was added dropwise to the above reaction solution. After the addition was complete, the temperature was raised to 25°C and the reaction was carried out under nitrogen protection for 12h. After the reaction was completed, the above reaction solution was extracted with a saturated sodium chloride-20% citric acid solution. After the extraction was completed, the reaction solution was spin-dried. The impurities in the crude product were separated by continuously adding mobile phases in different proportions. The mobile phase was petroleum ether and ethyl acetate in a volume ratio of 30:1. The product separation was detected by thin layer chromatography. When the mobile phase ratio was 2:1, the mobile phase flowing out of the silica gel column was collected and spin-dried to the intermediate product LA-OH.

[0046] PpIX (0.5 g, 0.2 mol) was added to a 100 mL eggplant-shaped bottle and dissolved with 30 mL of anhydrous dichloromethane. At 0 ° C, EDCI (1.4 g, 1.2 mol) and DMAP (0.8 g, 1.1 mol) were slowly added to the above reaction system and activated for 2 h under nitrogen protection. After activation, LA-OH was dissolved in 5 mL of anhydrous dichloromethane. After complete dissolution, LA-OH was added dropwise to the above reaction solution. After the addition was complete, the temperature was raised to 25 ° C and reacted for 12 h under nitrogen protection. After the reaction was completed, the above reaction solution was extracted with saturated sodium chloride-20% citric acid solution. After the extraction was completed, the reaction solution was spin-dried. The impurities in the crude product were separated by continuously adding mobile phases in different proportions. The mobile phase was petroleum ether and ethyl acetate in a volume ratio of 20:1. The product separation was detected by thin layer chromatography. When the mobile phase ratio was 1.5:1, the mobile phase flowing out of the silica gel column was collected and spin-dried to obtain the final product PPLA.

[0047] Mass spectrometry and nuclear magnetic resonance spectroscopy were used to determine the structure of the prodrug in Example 2. The results are as follows: Figure 3 and Figure 4 The results of NMR spectrum analysis are as follows: PPLA (C 74 H 102 N4O8H)

[0048] Figure 3 : 1 H NMR spectrum of PPLA. 1H NMR(400MHz,Chloroform-d)δ10.41–10.07(m,4H;4-methine protons),6.40(s,4H;4-CHCH2),5.63–5.09(m,12H;6-CH2),4.58–4.08(m,12H;6-CH2),3.84–3.36(m,12H;4-ring methyl),2.84–2.69(m,4H;CH2),2.40–2.23(m,4H,COCH2),2.11–1.93(m,8H;4-CH2),0.92–0.87(m,6H,2-CH3).

[0049] Figure 4 :Mass spectrometry results: ESI-MS (m / z): [M+Na] + =1175.77674.

[0050] Example 3: In vitro release experiment of docetaxel-protoporphyrin derivatives

[0051] Preparation of docetaxel-protoporphyrin prodrug co-assembled nanoparticles

[0052] Weigh 1 mg of each of the two prodrugs (PPLA and DSTG), mix them in a mass ratio of 1:1 between DSTG and PPLA, and dissolve them in 400 μL of anhydrous acetone with 20% (w / w) DSPE-PEG2k, and vortex to mix. Use a 1 mL syringe to slowly add the oil phase drop by drop into the stirred 2 mL of deionized water, and during the stirring process, each drug molecule forms co-assembled nanoparticles. The organic solvent acetone in the nanoformulation is removed by rotary evaporation, and finally the rice grains are fixed to 2 mL with deionized water to obtain prodrug co-assembled nanoparticles.

[0053] The in vitro release of docetaxel-protoporphyrin derivatives was investigated using 30% ethanol in pH 7.4 phosphate buffer (PBS) as the release medium: 1 mL of the above-prepared prodrug co-assembled nanoparticles (the content of docetaxel derivatives was 200 μg / mL) was added to 9 mL of the release medium, and samples were taken at set time points at 37°C, and the concentration of released docetaxel was determined by high performance liquid chromatography. 10 mM hydrogen peroxide was added to the release medium, and a certain concentration of lipase (1000 IU) and laser irradiation (100 mW / cm 2 , 2min) to investigate the release of DTX under different oxidative conditions.

[0054] The specific parameters of HPLC are as follows: chromatographic column: Ultimate XB-C18 (4.6×150mm, 5μm); column temperature: 28°C; detection wavelength: 227nm; mobile phase: acetonitrile: water = 70:30, v / v; injection volume: 20μL; flow rate: 1mL / min.

[0055] The results are as follows Figure 5-6 As shown, the experimental results show that the docetaxel-protoporphyrin derivative designed by the present invention has the characteristics of oxidation-sensitive drug release, can respond to the specific oxidative environment of tumor tissue, and can quickly release the most parent drug when irradiated with light, and has good ROS-lipase stimulation responsive release behavior, which is conducive to achieving tumor-specific release and improving anti-tumor efficacy.

[0056] Example 4: Preparation process of photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles

[0057] Schematic diagram of exosome extraction from adipocytes Figure 7 3T3-L1 cells were seeded in 100 mm 3 In a culture dish, culture at 37°C for 48 hours, replace with fresh culture medium for contact inhibition for 48 hours. After contact inhibition, replace the old culture medium with induction solution I for 48 hours, and then replace induction solution I with induction solution II for 48 hours. Then replace the culture medium containing 10% FBS every two days. After 4 days, the formation of mature adipocytes can be observed. The old culture medium is gently aspirated and treated with or without high fat for 4 hours. Then the supernatant is aspirated with a pipette and transferred to an ultrafiltration tube, and centrifuged at 3000rpm and 4°C for 30 minutes. The concentrated cell supernatant is centrifuged at 10000rpm and 4°C for 30 minutes to remove cell debris. Then centrifuge at 100000g at 4°C for 120 minutes, and the resulting precipitate is the high-fat adipocyte exosomes (hereinafter referred to as HEM) and non-high-fat treated adipocyte exosomes (hereinafter referred to as NEM).

[0058] High-fat conditions: After induction of adipocytes, the old culture medium was aspirated and replaced with fresh culture medium containing 0.3 μM monensin sodium and exosome-free serum, and cultured in a 37°C CO2 incubator for 4 h.

[0059] Induction solution I: 10% FBSDMEM + 1% double-antibody culture medium containing 0.5 mM IBMX, 1 μmol / L dexamethasone, 1 μg / mL insulin and 0.1 μmol / L rosiglitazone.

[0060] Induction solution II: 10% FBSDMEM + 1% double-antibody culture medium containing 1 μg / mL insulin.

[0061] Accurately weigh 1 mg of each of the two prodrugs (PPLA and DSTG), mix them in a mass ratio of 1:1 between DSTG and PPLA, mix with 20% (w / w) DSPE-PEG2k and dissolve in 400 μL of anhydrous acetone, and vortex to mix. Use a 1mL syringe to slowly drop the oil phase into the stirred 2mL of deionized water, and during the stirring process, each drug molecule co-assembles nanoparticles. Add dropwise to 2mL of deionized water at 800rpm, and remove the organic solvent acetone in the nanoformulation by rotary evaporation at 25°C. Finally, use deionized water to hold the rice grains to 2mL to obtain prodrug co-assembled nanoparticles (hereinafter referred to as NPs).

[0062] The BCA method was used to determine the quality of adipocyte exosomes. The standard curve of BCA is as follows: Figure 8 OD of exosomal proteins measured 560 is 1.585, substituting into Figure 8 The linear equation showed that the total protein concentration of the extracted exosomes was 1.42 μg / μL, the total volume was 8.5 mL, and the total mass of the extracted protein was 12.07 mg.

[0063] 2 mg of exosomes were mixed evenly with 1 mL of NPs solution and then added to the co-extruder. They were extruded through a 400 nm polycarbonate membrane for 20 times and then through a 200 nm polycarbonate membrane for 20 times to obtain photochemically integrated adipocyte exosome prodrug nanoparticles (HEMPs and NEMPs).

[0064] Example 5: Pharmacokinetics of photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles

[0065] Healthy female SD rats (200-220 g) were randomly divided into 4 groups, 3 rats in each group. 2.5 mg / kg (PpIX equivalent dose) of DTX / PpIX mixed solution, NPs, NEMPs and HEMPs preparations were injected into the tail vein. At the pre-designed time points (0.033, 0.083, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 h), about 500 μL of rat blood was collected through the eye socket and placed in a pre-anticoagulated EP tube, and centrifuged at 13000 rpm for 5 min, and the upper plasma was carefully removed and stored in a -80 ° C deep freezer.

[0066] Determination of the standard curve: take 50 μL of blank plasma, 50 μL of acetonitrile solution of different concentrations of photosensitizer, 100 μL of protein precipitant (acetonitrile containing 2‰ formic acid), vortex for 5 min, centrifuge at 13000 rpm for 5 min, take 200 μL of supernatant and add it to a black 96-well plate (n=3), and detect the fluorescence intensity (Ex=405 nm, Em=630 nm) with a multifunctional microplate reader.

[0067] Determination of photosensitizer blood concentration: take 50 μL of drug-containing plasma, 50 μL of acetonitrile, 100 μL of protein precipitant (acetonitrile containing 2‰ formic acid), vortex for 5 min, centrifuge at 13000 rpm for 5 min, take 200 μL of supernatant and add it to a black 96-well plate (n=3), and detect the fluorescence intensity (Ex=405 nm, Em=630 nm) with a multifunctional microplate reader.

[0068] Pharmacokinetic data processing: The fluorescence intensity was substituted into the standard curve to calculate the blood concentration of the photosensitizer, and the half-life (t 1 / 2 ), area under the concentration-time curve (AUC(0-t)), peak blood concentration (Cmax) and other pharmacokinetic parameters.

[0069] The results are as follows Fig. 9 As shown, due to the short half-life (t 1 / 2 , 0.18 hours), the solution was quickly eliminated from the blood. In contrast, HEMPs and NEMPs prolonged blood circulation. The prodrug area under the curve (AUC(0-t)) in NPs, NEMPs and HEMPs was 18.5 times, 35.7 times and 53.3 times higher than that in the mixed solution. Due to the poor colloidal stability of NPs, the AUC of NPs was lower compared with HEMPs and NEMPs. The photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles designed by the present invention are of great significance for enhancing and improving the pharmacokinetic parameters of the loaded drugs.

[0070] Example 6: Pharmacodynamics of photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles

[0071] The hair on the lower right back of male C57BL / 6 mice was shaved, and Hepa1-6 cells (density 5 million / mouse) were injected subcutaneously. When the tumor volume grew to 100mm 3 The mice were divided into 9 groups, 5 mice in each group. They were set up as saline group, Sol group (DTX / PpIX mixed solution), Sol(+) group (DTX / PpIX mixed solution + laser irradiation), NPs group, NPs(+) group, NEMPs group, NEMPs(+) group, HEMPs group and HEMPs(+) group (PpIX equivalent dose 2.5 mg / kg), and the drugs were given every other day for a total of 5 times. 0.2 mW / cm 2 Laser. The tumor volume (volume = short diameter × short diameter × long diameter / 2) and body weight of mice were measured and recorded every other day. On the 12th day, the mice were killed, dissected, photographed, weighed, and the tumor-bearing rate was calculated (tumor-bearing rate = tumor weight / body weight × 100%). When the tumor volume of the tumor-bearing mice in the saline group reached 1500mm 3 When the experiment is about 30 minutes, the experiment will be terminated based on animal ethics guidelines.

[0072] The results are as follows Figure 10-11 As shown, after 5 treatments with an interval of 1 day, the anti-tumor effect was Fig.10 The tumors in the saline group grew rapidly and had the largest tumor volume. After the administration, the tumor volume reached 1500mm 3 . The antitumor effect of the illumination group was significantly enhanced compared with the non-illumination group, which was attributed to the self-promoting drug release of chemotherapeutic drugs caused by illumination and the redox damage and lipid peroxidation effects of photosensitizers. Among the illumination groups, the Sol(+) group showed the weakest antitumor effect, which was due to the rapid clearance of the solution after entering the systemic circulation, resulting in less drug accumulation in the tumor site. Compared with the Sol(+) group, NPs(+) showed a stronger antitumor effect, which was attributed to the longer blood circulation time and EPR effect of the nanoparticles. HEMPs(+) showed the strongest antitumor effect, and only two doses could almost completely inhibit tumor growth, with almost no change in tumor volume. This can be attributed to two points: (1) the adipocyte exosome membrane endowed Ad-exos NPs with targeting function to liver cancer cells, allowing the drug to accumulate efficiently in the tumor site; (2) the specific drug release conferred by the single sulfide bond and triglyceride structure sensitive to the tumor microenvironment.

[0073] Example 7: In vivo distribution of photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles

[0074] The hair on the lower right back of male C57BL / 6 mice was shaved and Hepa1-6 cells (density 5 million / mouse) were injected subcutaneously. When the tumor volume grew to 200mm 3 48 mice with tumors of similar size were randomly selected and divided into 16 groups (4 time points, 4 preparations at each time point), with 3 mice in each group. 2.5 mg / kg (equivalent dose of PpIX) of DTX / PpIX mixed solution, NPs, NEMPs and HEMPs preparations were injected into the tail vein, and the mice were kept in the dark. The mice were killed by cervical dislocation at 4h, 8h, 12h and 24h, and the heart, liver, spleen, lung, kidney and tumor were removed and placed in a small animal in vivo imager to measure PpIX fluorescence. The PpIX accumulated in each organ and tumor tissue was quantified using IVIS software.

[0075] The results are as follows Fig.12 As shown, after administration, the solution was quickly cleared from the blood and the tumor accumulation decreased. Compared with NPs, HEMPs showed stronger fluorescence at the tumor site and accumulated the most at 8h, a trend that was consistent with the quantitative fluorescence results of tumor tissue. In addition, at 24h after administration, the fluorescence intensity of HEMPs in tumor tissue was still elevated, 1.32 times higher than that of NPs. This can be attributed to the enhanced tumor targeting function of high-fat adipocyte exosomes.

[0076] However, the accumulation of prodrugs labeled with near-infrared fluorescent probe PPLA in tumors does not directly reflect the intratumoral release of DSTG. Therefore, the level of DTX released in tumors was further investigated. Fig.12 As shown, the amount of DTX released into the tumor was the highest in the irradiated HEMPs group. These results suggest that adipocyte exosome camouflage has a triple advantage: ensuring prolonged blood circulation time, improving tumor accumulation, and precisely targeting drug delivery to the tumor.

Claims

1. Photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles, characterized in that: The nanoparticles have a bionic shell of fat cell exosomes, which enables them to exist stably under normal physiological conditions, target the tumor site after intravenous injection, and achieve specific release of the parent drug in tumor cells under the abnormally high oxidation environment in tumor cells; the prodrug is composed of a protoporphyrin derivative and a docetaxel derivative.

2. The photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles according to claim 1, characterized in that: The docetaxel derivative has dual sensitivity to oxidation and lipase and is a compound as shown below or a pharmaceutically acceptable salt thereof; 3. The photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles according to claim 2, characterized in that: The preparation method of the docetaxel derivative is prepared by the following steps: First, linoleic acid and 1,3-dihydroxyacetone were esterified at room temperature under the catalysis of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and 4-dimethylaminopyridine to obtain compound 1; Then, compound 1 undergoes a cyclization reaction with monothiodipropionic acid in the presence of acetic anhydride. This reaction is carried out under N2 protection throughout the process, and compound 2 is separated; Compound 2 was activated at 0°C under the catalysis of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and 4-dimethylaminopyridine, and docetaxel was added. The reaction was carried out at room temperature, and the final product was separated and purified.

4. The photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles according to claim 1, characterized in that: The protoporphyrin derivative has good fat solubility and is a compound as shown below or a pharmaceutically acceptable salt thereof; 5. The photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles according to claim 4, characterized in that: The preparation method of the protoporphyrin derivative is prepared by the following steps: Linoleic acid was reacted with stirring at 0°C under the catalysis of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and 4-dimethylaminopyridine. After the reaction, ethylene glycol was added and the temperature was raised to 25°C and stirred to react to obtain compound 1. PpIX was reacted at 0°C under the catalysis of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and 4-dimethylaminopyridine. After the reaction, compound 1 was added, the temperature was raised to 25°C, and the reaction was stirred. The final product was separated and purified.

6. The method for preparing the photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles according to claim 1, characterized in that: 3T3-L1 cells were seeded in 100 mm 3 In a culture dish, high-fat adipocyte exosomes and non-high-fat treated adipocyte exosomes were extracted, and the protoporphyrin derivative and the docetaxel derivative were weighed, mixed in a mass ratio of 1:1, and fixed to 2 mL with deionized water to obtain prodrug co-assembled nanoparticles; The BCA method was used to determine the quality of adipocyte exosomes, and the OD was measured according to the standard curve. 560 The values ​​were substituted into the linear equation to calculate the exosome concentration, and high-fat and non-high-fat photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles were prepared by co-extrusion at a ratio of 1 mg exosomes: 0.5 mg prodrug co-assembled nanoparticles.

7. Use of the photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles according to claim 1 in the preparation of a drug delivery system.

8. Use of the photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles according to claim 1 in the preparation of cancer targeted therapeutic drugs.

9. Use of the photochemically integrated adipocyte exosome biomimetic prodrug nanoparticles according to claim 1 in the preparation of an injection, oral administration or local administration system.

Citation Information

Patent Citations

  • Construction of intravenous-injection self-assembled nano-particles of triglyceride prodrug

    CN112494458A

  • Docetaxel-fatty alcohol small-molecule prodrug and construction of self-assembled nanoparticles of docetaxel-fatty alcohol small-molecule prodrug

    CN115252803A

  • Docetaxel prodrug anti-tumor preparation

    CN116327968A

  • Docetaxel-fatty alcohol small molecule prodrug and construction of self-assembled nanoparticles thereof

    WO2022227556A1